DFO
OLMA icon

Duquesne Family Office’s Olema Pharmaceuticals OLMA Stock Holding History

Duquesne Family Office’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3M Hold
986,827
– – 0.24% 69
2026
Q1 		$14.7M Buy
+986,827
New +$22M 0.44% 47

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Duquesne Family Office's OLMA Position: Q2 2026 in Review

Duquesne Family Office held its Olema Pharmaceuticals (OLMA) position steady in Q2 2026 at 986,827 shares worth $12.3M. The position accounts for 0.24% of the portfolio, ranked #69.

Duquesne Family Office first reported a position in OLMA in Q1 2026 and has held it in 2 quarters since. The position peaked at $14.7M in Q1 2026. 186 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Duquesne Family Office held 986,827 shares of Olema Pharmaceuticals worth $12.3M as of Q2 2026.
  • Duquesne Family Office left its Olema Pharmaceuticals share count unchanged in Q2 2026.
  • Olema Pharmaceuticals made up 0.24% of Duquesne Family Office's portfolio in Q2 2026, its #69 holding.
  • Duquesne Family Office first reported a position in Olema Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Duquesne Family Office's Olema Pharmaceuticals position peaked at $14.7M in Q1 2026.
  • 186 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Duquesne Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.